NCT04000737 2025-04-13
YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Yiviva Inc.
Phase 2 Completed
Yiviva Inc.
Lion TCR Pte. Ltd.
Mina Alpha Limited
University of Washington
Third Affiliated Hospital, Sun Yat-Sen University
Merck Sharp & Dohme LLC
Tongji University